---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-087233"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-04-21T23:59:59+00:00"
generated_at: "2026-05-23T10:02:07.989017+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jazz completes $935M acquisition of Chimerix, adds dordaviprone to pipeline

## Summary
- Acquisition completed for ~$935M cash; $8.55 per share.
- Dordaviprone for H3 K27M-mutant diffuse glioma under FDA Priority Review; PDUFA date Aug 18, 2025.
- If approved, could be first FDA-approved therapy for that indication; potential near-term opportunity.
- Also in Phase 3 ACTION trial for newly diagnosed, non-recurrent diffuse glioma.

## SEC filing metadata
- accession: 0001193125-25-087233
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-04-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/0001193125-25-087233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/d887871d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-087233
- JSON: https://secwatch.observer/filing/0001193125-25-087233.json
- Plain text: https://secwatch.observer/filing/0001193125-25-087233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.